Safety and Efficacy Study of Ravulizumab in Adults | Clinical Research Studies Listing

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Recruiting

18 years - 99 years

All

Phase 3

175 participants needed

1 Location

Brief description of study

The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Myasthenia Gravis
Age: 18 years - 99 years
Gender: All

Male and Female, Age 18 or older, Diagnosis of Myasthenia Gravis

Updated on 04 Aug 2024. Study ID: 834121

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Brief description of study

Eligibility of study

Find a site

Interested in the study